Abstract: Objective: To evaluate the therapeutic value of neoadjuvant chemotherapy for patients with stage Ⅱ and Ⅲ breast cancer. Methods: A total of 26 breast cancers patients at stage Ⅱ and Ⅲ, pathologically proven during September 1994 to September 1999, were studied, which were divided into neoadjuvant chemotherapy group (A) and control group (B). The impact of neoadjuvant chemotherapy on surgical methods choice, local control rate, 5-year overall survival rate (OS) and 5-year diseasefree survival rate (DFS) were analyzed and the therapeutic value of neoadjuvant chemotherapy on the breast cancer patients at stage Ⅱ and Ⅲ were discussed. Results: For patients of stage Ⅱ, the rate of breast conservation significantly increased from 24.7% to 44.6% (P=0.000) and there was no significant difference between group A and B (P=0.525, 0.581) in 5-year OS and DFS. For patients of stage Ⅲ, the 5-year OS (62.9%) and DFS(58.1%) in group A were greatly higher than that in group B (39.5% and 32.6%) (P=0.014, 0.010). The imperative dermatoplasty rate of the breast cancer patients at stage Ⅱ and Ⅲ in Group A decrease greatly (P=0.000、0.000) and the 3-year local relapse and metastasis rate were lower than group B (P=0.035、0.027). Conclusion: The neoadjuvant chemotherapy can improve potential rate of breast conservation, reduce the rate of imperative dermatoplasty, local-regional recurrence rate and distant metastasis for the patients with stage Ⅱ and Ⅲ breast cancer, and can also improve the 5-year survival rate for the patients of stage Ⅲ.